Taiho’s CMO Dr Keer on positive REZILIENT3 data for zipalertinib combo
Dr Keer discusses PFS gains, survival data, quality of life, and key subgroup findings for zipalertinib combo in previously untreated, advanced NSCLC.
Drug Development
J&J’s Mark Graham on advancing nipocalimab as treatment for SLE
Pfizer receives EC approval for Hympavzi to treat haemophilia
Contineum’s MS drug falls short in Phase II trial
Neurocrine’s depression treatment misses main goal in Phase II study
China accounts for one-fifth of global drugs in development
Imunon’s Phase III-stage IL-12 gene therapy alters tumour microenvironment in ovarian cancer
Four drugs race for first bispecific ADC approval
